There are several factors that could make FRLF an attractive play when looked at as a whole.
1) Hempology products, which sales will launch on November 20, 2017, could be a major revenue generator for FRLF in the coming quarters, and could quickly improve their overall financial outlook going forward. The Company is expecting to sell $500,000 through their www.myhempology.com website through the end of their fiscal year, June 30, 2018.
2) Their acquisition of LaMarihuana.com and Marihuana-Medicinal.com could also expand Hempology’s customer base, a nd with the 1.7 million monthly visitors the company is has projected $250,000 ad and product sales. These sites have an amazing reach throughout the highly attractive Latin America market. Of the monthly visitors 70%, 1.2 million, are out of Central and South America. The sites also have in excess of 1.2 million Facebook Likes.
3) Green Market Europe S. L. is also expected to bring a major jump in revenues before the end of Freedom Leaf’s fiscal year with projection of $1.0 million in revenue, and could position FRLF footprint in the European market.
4) Finally, the appointment of Mr. Pelosi is a real boost of credibility for the company, but also opens the door for FRLF to become a major lobbying force for the legalization of marijuana and cannabis on the State and Federal level. With Mr Pelosi’s strength in good corporate governance Freedom Leaf aims to be the example of corporate governance for other public companies in the Cannabis and Industrial Hemp Industry.
Mr. Pelosi experience in building so und corporate governance, sustainability, and public policy could make FRLF one of the safer plays compliance wise for investors interested in this sector.
5) The publishing of a high quality magazine continues to provide strong credibility to the company. The magazine has become a media platform that drives companies to seek Freedom Leaf to be acquired or accelerated. Freedom Leaf only acquires those who provide serious revenue growth to the company. The magazine also becomes a champion and potential lobbying force for the legalization of marijuana, and is quickly making Freedom Leaf a well known name within this industry.
Based on the appointment of Mr. Pelosi as the new Chairman of the Board, and taking in all of their other operations and how they may fit together, Ludlow Research has raised its short-term ‘speculative’ target on FRLF from $0.10+ to $0.25 per share.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.